Cargando…

Changes in HER3 expression profiles between primary and recurrent gynecological cancers

BACKGROUND: Human epidermal growth factor receptor-3 (HER3) is a member of the epidermal growth factor receptor family of receptor tyrosine kinases, and its overexpression is associated with inferior prognosis in several cancers. However, it is unclear whether HER3 expression status changes in tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojima, Yuki, Sudo, Kazuki, Yoshida, Hiroshi, Yazaki, Shu, Tokura, Momoko, Mizoguchi, Chiharu, Okuma, Hitomi S., Kita, Shosuke, Yamamoto, Kasumi, Nishikawa, Tadaaki, Noguchi, Emi, Shimoi, Tatsunori, Tanase, Yasuhito, Uno, Masaya, Ishikawa, Mitsuya, Kato, Tomoyasu, Koyama, Kumiko, Kobayashi, Maki, Kakegawa, Tomoya, Fujiwara, Yasuhiro, Yonemori, Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898949/
https://www.ncbi.nlm.nih.gov/pubmed/36737733
http://dx.doi.org/10.1186/s12935-022-02844-z
_version_ 1784882540152094720
author Kojima, Yuki
Sudo, Kazuki
Yoshida, Hiroshi
Yazaki, Shu
Tokura, Momoko
Mizoguchi, Chiharu
Okuma, Hitomi S.
Kita, Shosuke
Yamamoto, Kasumi
Nishikawa, Tadaaki
Noguchi, Emi
Shimoi, Tatsunori
Tanase, Yasuhito
Uno, Masaya
Ishikawa, Mitsuya
Kato, Tomoyasu
Koyama, Kumiko
Kobayashi, Maki
Kakegawa, Tomoya
Fujiwara, Yasuhiro
Yonemori, Kan
author_facet Kojima, Yuki
Sudo, Kazuki
Yoshida, Hiroshi
Yazaki, Shu
Tokura, Momoko
Mizoguchi, Chiharu
Okuma, Hitomi S.
Kita, Shosuke
Yamamoto, Kasumi
Nishikawa, Tadaaki
Noguchi, Emi
Shimoi, Tatsunori
Tanase, Yasuhito
Uno, Masaya
Ishikawa, Mitsuya
Kato, Tomoyasu
Koyama, Kumiko
Kobayashi, Maki
Kakegawa, Tomoya
Fujiwara, Yasuhiro
Yonemori, Kan
author_sort Kojima, Yuki
collection PubMed
description BACKGROUND: Human epidermal growth factor receptor-3 (HER3) is a member of the epidermal growth factor receptor family of receptor tyrosine kinases, and its overexpression is associated with inferior prognosis in several cancers. However, it is unclear whether HER3 expression status changes in tumor tissue at recurrence. Therefore, this study aimed to evaluate the changes in HER3 expression between primary and recurrent status in gynecological cancers. METHODS: This retrospective study used matched-pair tissues of gynecological cancer patients at initial diagnosis and at recurrence. Immunohistochemical (IHC) scores of 3 + or 2 + were termed “HER3-high”, while IHC scores of 1 + or 0 were designated as “HER3-low/zero”. RESULTS: A total of 86 patients (40 with ovarian cancers, 32 with endometrial cancers, and 14 with cervical cancers) were included in this study. In ovarian cancer, 67.5% and 80.0% of the patients received a HER3-high at initial and recurrent diagnosis, respectively. The H-score was significantly increased at recurrence (p = 0.004). The proportion of HER3-high endometrial cancer patients increased from 46.9% at initial diagnosis to 68.8% at recurrence, and the H-score tended to increase at recurrence (p = 0.08). The fraction of HER3-high-rated cervical cancer patients remained unchanged at 85.7% both at initial and recurrent diagnosis. The discordance rate of HER3 expression detection in initial and recurrent diagnosis samples was 27.5%, 53.1%, and 14.3% for ovarian, endometrial, and cervical cancers, respectively. Ovarian and endometrial cancers with a HER3-high recurrent score tended to show shorter median survival time than those with a HER3-low/zero recurrent rating. CONCLUSION: Our findings suggest that, in main types of gynecological cancers, the proportion of patients having a HER3-high score increased from initial to recurrent diagnosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02844-z.
format Online
Article
Text
id pubmed-9898949
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98989492023-02-05 Changes in HER3 expression profiles between primary and recurrent gynecological cancers Kojima, Yuki Sudo, Kazuki Yoshida, Hiroshi Yazaki, Shu Tokura, Momoko Mizoguchi, Chiharu Okuma, Hitomi S. Kita, Shosuke Yamamoto, Kasumi Nishikawa, Tadaaki Noguchi, Emi Shimoi, Tatsunori Tanase, Yasuhito Uno, Masaya Ishikawa, Mitsuya Kato, Tomoyasu Koyama, Kumiko Kobayashi, Maki Kakegawa, Tomoya Fujiwara, Yasuhiro Yonemori, Kan Cancer Cell Int Research BACKGROUND: Human epidermal growth factor receptor-3 (HER3) is a member of the epidermal growth factor receptor family of receptor tyrosine kinases, and its overexpression is associated with inferior prognosis in several cancers. However, it is unclear whether HER3 expression status changes in tumor tissue at recurrence. Therefore, this study aimed to evaluate the changes in HER3 expression between primary and recurrent status in gynecological cancers. METHODS: This retrospective study used matched-pair tissues of gynecological cancer patients at initial diagnosis and at recurrence. Immunohistochemical (IHC) scores of 3 + or 2 + were termed “HER3-high”, while IHC scores of 1 + or 0 were designated as “HER3-low/zero”. RESULTS: A total of 86 patients (40 with ovarian cancers, 32 with endometrial cancers, and 14 with cervical cancers) were included in this study. In ovarian cancer, 67.5% and 80.0% of the patients received a HER3-high at initial and recurrent diagnosis, respectively. The H-score was significantly increased at recurrence (p = 0.004). The proportion of HER3-high endometrial cancer patients increased from 46.9% at initial diagnosis to 68.8% at recurrence, and the H-score tended to increase at recurrence (p = 0.08). The fraction of HER3-high-rated cervical cancer patients remained unchanged at 85.7% both at initial and recurrent diagnosis. The discordance rate of HER3 expression detection in initial and recurrent diagnosis samples was 27.5%, 53.1%, and 14.3% for ovarian, endometrial, and cervical cancers, respectively. Ovarian and endometrial cancers with a HER3-high recurrent score tended to show shorter median survival time than those with a HER3-low/zero recurrent rating. CONCLUSION: Our findings suggest that, in main types of gynecological cancers, the proportion of patients having a HER3-high score increased from initial to recurrent diagnosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02844-z. BioMed Central 2023-02-03 /pmc/articles/PMC9898949/ /pubmed/36737733 http://dx.doi.org/10.1186/s12935-022-02844-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kojima, Yuki
Sudo, Kazuki
Yoshida, Hiroshi
Yazaki, Shu
Tokura, Momoko
Mizoguchi, Chiharu
Okuma, Hitomi S.
Kita, Shosuke
Yamamoto, Kasumi
Nishikawa, Tadaaki
Noguchi, Emi
Shimoi, Tatsunori
Tanase, Yasuhito
Uno, Masaya
Ishikawa, Mitsuya
Kato, Tomoyasu
Koyama, Kumiko
Kobayashi, Maki
Kakegawa, Tomoya
Fujiwara, Yasuhiro
Yonemori, Kan
Changes in HER3 expression profiles between primary and recurrent gynecological cancers
title Changes in HER3 expression profiles between primary and recurrent gynecological cancers
title_full Changes in HER3 expression profiles between primary and recurrent gynecological cancers
title_fullStr Changes in HER3 expression profiles between primary and recurrent gynecological cancers
title_full_unstemmed Changes in HER3 expression profiles between primary and recurrent gynecological cancers
title_short Changes in HER3 expression profiles between primary and recurrent gynecological cancers
title_sort changes in her3 expression profiles between primary and recurrent gynecological cancers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898949/
https://www.ncbi.nlm.nih.gov/pubmed/36737733
http://dx.doi.org/10.1186/s12935-022-02844-z
work_keys_str_mv AT kojimayuki changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT sudokazuki changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT yoshidahiroshi changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT yazakishu changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT tokuramomoko changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT mizoguchichiharu changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT okumahitomis changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT kitashosuke changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT yamamotokasumi changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT nishikawatadaaki changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT noguchiemi changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT shimoitatsunori changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT tanaseyasuhito changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT unomasaya changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT ishikawamitsuya changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT katotomoyasu changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT koyamakumiko changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT kobayashimaki changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT kakegawatomoya changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT fujiwarayasuhiro changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers
AT yonemorikan changesinher3expressionprofilesbetweenprimaryandrecurrentgynecologicalcancers